•  
  •  
  •  
  •  

2026-07-21 18:34:13

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Nureca Limited Turns Around in Q1 FY27: Posts Profit Before Tax of INR 44.33 Million as Revenues Surge
  • Anthem Biosciences Limited Reports Q1 FY27 Net Profit of ₹1,199 Million on Revenues of ₹4,182 Million
  • ANVISA Approval for CuraTeQ Biologics' Biosimilars Manufacturing Facility
  • JSW Infrastructure Posts 18% Revenue Growth to ₹1,445 Crore in Q1 FY27; Operating EBITDA Reaches ₹674 Crore
  • TVS Holdings Reports Net Profit Jump of 73.8% to ₹1,173.58 Crore for Q1 FY27

Keywords Selected:  Inspection

Stock Report

  • Wanbury Limited gets 6 observations from USFDA after cGMP inspection at Tanuku facility
  • Completion of US-FDA Inspection at Sterile Product Division facility at Bengaluru
  • US FDA inspection at Glenmark Pharmaceuticals Ltd's manufacturing facility in Goa, India
  • Completion of US FDA Inspection at Auroactive Pharma Pvt Ltd
  • Concord Biotech Ltd successfully completes PPB and NDA inspection
  • Concord Biotech Ltd completes ANVISA Inspection conducted by the Brazilian Health Regulatory Agency at the Limbasi API Manufacturing Facility
  • USFDA inspection at Cipla Ltd's manufacturing facility in Verna, Goa, India
  • Wanbury's Tanuku unit successfully completes Quality Inspection by TGA
  • US FDA Inspection at Alkem Laboratories Ltd's CRO facility located at Taloja
  • US FDA Inspection at Alkem Laboratories Ltd's manufacturing facility located at Amaliya, Daman
  • Solara announces successful closure of US FDA inspection of its Puducherry Facility with continued state of cGMP compliance
  • USFDA inspection at Rubicon Research Ltd's R&D Facility
  • USFDA inspection at Somerset facility of Lupin Ltd
  • USFDA inspection at Cipla Ltd's manufacturing facility in Goa, India
  • Morepen Secures Fourth Consecutive USFDA Inspection with Zero Observations
  • Granules Life Sciences Receives VAI Classification following US FDA Inspection
  • Unit-IV of APL Healthcare Ltd classified as VAI by the US FDA
  • Alembic Pharmaceuticals Ltd receives 2 observations for Karakhadi Injectable Facility
  • USFDA inspection at the manufacturing facility of Enzene Biosciences Limited
  • Strides Pharma Inc's Chestnut Ridge facility gets 4 observations from USFDA
  • US FDA determines Sun Pharma's Baska facility inspection classification as OAI
  • Successful completion of USFDA inspection at Vizag facility
  • Apitoria Pharma Pvt Ltd receives 3 observations from USFDA for Unit-V
  • GMP Inspection by Malta Medicines Authority at Alkem's manufacturing facility located at Daman, India

Latest Post

  • Nureca Limited Turns Around in Q1 FY27: Posts Profit Before Tax of INR 44.33 Million as Revenues Surge
  • Anthem Biosciences Limited Reports Q1 FY27 Net Profit of ₹1,199 Million on Revenues of ₹4,182 Million
  • ANVISA Approval for CuraTeQ Biologics' Biosimilars Manufacturing Facility
  • JSW Infrastructure Posts 18% Revenue Growth to ₹1,445 Crore in Q1 FY27; Operating EBITDA Reaches ₹674 Crore
  • TVS Holdings Reports Net Profit Jump of 73.8% to ₹1,173.58 Crore for Q1 FY27


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025